Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Emilie M. J. van Brummelen"'
Autor:
Igor Radanovic, Naomi Klarenbeek, Robert Rissmann, Geert Jan Groeneveld, Emilie M. J. van Brummelen, Matthijs Moerland, Jacobus J. Bosch
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AimTraditionally, early phase clinical trials in oncology have been performed in patients based on safety risk-benefit assessment. Therapeutic transition to immuno-oncology may open new opportunities for studies in healthy volunteers, which are condu
Externí odkaz:
https://doaj.org/article/05c5b23e725044ca9151f80660d82f26
Autor:
Johan L. Van Der Plas, Pauline Verdijk, Emilie M. J. Van Brummelen, Rienk E. Jeeninga, Meta Roestenberg, Jacobus Burggraaf, Ingrid M.C. Kamerling
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 6, Pp 1322-1326 (2020)
One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity in healthy adults. Healthy adults will have preexisting levels of serum neutralizing antibodies t
Externí odkaz:
https://doaj.org/article/5b502c9fc390473da186d46f3123535f
Autor:
Soma Makai-Bölöni, Eva Thijssen, Emilie M. J. van Brummelen, Geert J. Groeneveld, Robert J. Doll
Publikováno v:
PLoS ONE, Vol 16, Iss 12 (2021)
Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects almost 2% of the population above the age of 65. To better quantify the effects of new medications, fast and objective methods are needed. Touchscreen-based tapping ta
Externí odkaz:
https://doaj.org/article/761870305e054ca3b5f8c53444eb0f69
Autor:
Geert Jan Groeneveld, Erica S. Klaassen, Ingrid M C Kamerling, Emilie M. J. van Brummelen, Vanessa Ville, Annie-Claude Benichou, Cécile L. Berends, Kirsten R. Bergmann, Laurence M Moss, Victor Juarez-Perez
Publikováno v:
British Journal of Clinical Pharmacology, 88(1), 103-114. WILEY
Aim Dual enkephalinase inhibitors (DENKIs) are involved in the regulation of nociception via opioid receptors. The novel compound STR-324 belongs to the DENKI pharmacological class. This first-in-human study evaluated the safety, tolerability, pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::203c2f72a6fdb6cb1920e64b447cdfa4
https://doi.org/10.1111/bcp.14931
https://doi.org/10.1111/bcp.14931
Autor:
Wadim M. I. de Boon, Emilie M. J. van Brummelen, Robert Doll, Dimitrios Ziagkos, Petteri Kolehmainen, Geert Jan Groeneveld, Teppo Huttunen, Ellen P. Hart
Publikováno v:
Journal of Clinical Movement Disorders, Vol 7, Iss 1, Pp 1-11 (2020)
Journal of Clinical Movement Disorders
Journal of Clinical Movement Disorders
Background To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer products such as smartphones and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78d757a80d642322e5c7b09690d8f22
http://link.springer.com/article/10.1186/s40734-020-00086-7
http://link.springer.com/article/10.1186/s40734-020-00086-7
Autor:
Pauline Verdijk, Meta Roestenberg, Ingrid M C Kamerling, Emilie M. J. van Brummelen, Johan L. van der Plas, Rienk E. Jeeninga, Jacobus Burggraaf
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity in healthy adults. Healthy adults will have preexisting levels of serum neutralizing antibodies t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f825e2f328fc5f276e2656aa59f70b3c
http://europepmc.org/articles/PMC7482755
http://europepmc.org/articles/PMC7482755
Publikováno v:
Clinical and translational science. 15(4)
Selective inhibition of certain voltage-gated sodium channels (Na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56d3cf50086e8d3985f02b5539f39cd0
https://pubmed.ncbi.nlm.nih.gov/34958174
https://pubmed.ncbi.nlm.nih.gov/34958174
Autor:
Michelle Mellion, Sander Brooks, Diego Cadavid, Shane Raines, Michelle Hage, Geert Jan Groeneveld, Cécile Berends, William G Tracewell, Adefowope Odueyungbo, Lorin A. Thompson, Lucienne Ronco, Michiel J van Esdonk, Lisa Pagan, Umesh A. Badrising, Emilie M J van Brummelen, Baziel G.M. van Engelen
Publikováno v:
British Journal of Clinical Pharmacology, 87(12), 4658-4669. WILEY
Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). Methods This study included Part A: 10 healthy volunteers randomized to single oral doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc884dc6eac870563f6d4cc46fe9b44f
http://hdl.handle.net/1887/3248780
http://hdl.handle.net/1887/3248780
